NCT01251653 - A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Neoplasms

Interventions

DRUG

Afatinib

Maximum Tolerated Dose of Afatinib in combination with gemcitabine

DRUG

Afatinib

Maximum Tolerated Dose of Afatinib in combination with gemcitabine

DRUG

docetaxel

Maximum Tolerated Dose of Afatinib in combination with docetaxel

DRUG

gemcitabine

Maximum Tolerated Dose of Afatinib in combination with gemcitabine

Trial Locations (3)

1200.93.33002 Boehringer Ingelheim Investigational Site, Dijon

1200.93.33001 Boehringer Ingelheim Investigational Site, Saint-Herblain

1200.93.33003 Boehringer Ingelheim Investigational Site, Toulouse